Dey L.P. Settles State of Utah Pricing Litigation
NAPA, Calif., Sept. 17 /PRNewswire-FirstCall/ — Dey, L.P. today announced that it has settled a lawsuit brought against it and other companies by the State of Utah in October 2005 pertaining to Medicaid reimbursements paid by the state to pharmacists and other healthcare providers. In exchange for a full release of claims, Dey has agreed to pay approximately $1 million.
As part of the 2007 acquisition agreement between Mylan Inc. (Dey’s parent company) and Merck KGaA (Dey’s former parent company), Merck KGaA is responsible for paying the full amount of this settlement as well as all costs and other expenses associated with pending and future-related Medicaid reimbursement lawsuits involving Dey.
As part of the settlement, the state acknowledges that the settlement does not constitute admission or evidence of fault, liability or unlawful conduct by Dey.
Dey L.P., a subsidiary of Mylan Inc. (Nasdaq: MYL), is a specialty pharmaceutical company focused on the development, manufacturing and marketing of prescription drug products for the treatment of respiratory diseases, respiratory-related allergies and emergency care medicine. As the U.S. leader in sales of nebulized respiratory medication, Dey puts patients first through its development of innovative and affordable therapies. The Web sites for Dey L.P. include www.dey.com, www.accuneb.com, www.curosurfusa.com, www.cyanokit.com, www.duoneb.com, www.epipen.com and www.perforomist.com.
SOURCE Dey L.P.